Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 6, 2016, Pages 662-670

  Elewa, Hazem ^a   Ahmed, Dina ^b   Barnes, Geoffrey D ^c  

^a Qatar University ^*  (Qatar)

^b HAMAD GENERAL HOSPITAL   (Qatar)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

acute coronary syndrome; antiplatelet; antithrombotic; atrial fibrillation; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CORONARY STENTING; DRUG SUBSTITUTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; COMPLICATION; CORONARY BLOOD VESSEL; ORAL DRUG ADMINISTRATION; STENT; SURGERY;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; CORONARY VESSELS; FIBRINOLYTIC AGENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; STENTS; THROMBOSIS;

EID: 84974782797     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0036-1571337     Document Type: Article

References (52)

1. Go A. S., Hylek E. M., Phillips K. A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA: 2001; 285 18 2370 2375
2. Kannel W. B., Benjamin E. J. Status of the epidemiology of atrial fibrillation. Med Clin North Am: 2008; 92 1 17 40, ix i x.
3. Stewart S., Hart C. L., Hole D. J., McMurray J. J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart: 2001; 86 5 516 521
4. Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med: 2007; 146 12 857 867
5. Connolly S., Pogue J., Hart R., et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet: 2006; 367 9526 1903 1912
6. Lip G. Y., Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J: 2014; 35 28 1844 1855
7. Skjoth F., Larsen T. B., Rasmussen L. H., Lip G. Y. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost: 2014; 111 5 981 988
8. Spinler S. A., Shafir V. New oral anticoagulants for atrial fibrillation. Circulation: 2012; 126 1 133 137
9. Camm A. J., Lip G. YH, De Caterina R., et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J: 2012; 33 21 2719 2747
10. You J. J., Singer D. E., Howard P. A., et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e531S e575S
11. Capodanno D., Angiolillo D. J. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv: 2014; 7 1 113 124
12. Sorensen R., Gislason G. Triple antithrombotic therapy: risky but sometimes necessary. Rev Esp Cardiol (Engl Ed): 2014; 67 3 171 175
13. Mega J., Carreras E. T. Antithrombotic therapy: triple therapy or triple threat? Hematology (Am Soc Hematol Educ Program): 2012; 2012 547 552
14. Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med: 2001; 345 7 494 502
15. Franchi F., Angiolillo D. J. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol: 2015; 12 1 30 47
16. Giorgi M. A., Cohen Arazi H., Gonzalez C. D., Di Girolamo G. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother: 2011; 12 8 1285 1295
17. Wallentin L., Becker R. C., Budaj A., et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med: 2009; 361 11 1045 1057
18. Wiviott S. D., Braunwald E., McCabe C. H., et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med: 2007; 357 20 2001 2015
19. Lip G. Y., Windecker S., Huber K., et al. Document Reviewers. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J: 2014; 35 45 3155 3179
20. O'Gara P. T., Kushner F. G., Ascheim D. D., et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation: 2013; 127 4 e362 e425
21. Bonaca M. P., Bhatt D. L., Cohen M., et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med: 2015; 372 19 1791 1800
22. Mauri L., Kereiakes D. J., Yeh R. W., et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med: 2014; 371 23 2155 2166
23. Palmerini T., Benedetto U., Bacchi-Reggiani L., et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet: 2015; 385 9985 2371 2382
24. Nieuwlaat R., Capucci A., Camm A. J., et al. European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J: 2005; 26 22 2422 2434
25. Nabauer M., Gerth A., Limbourg T., et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace: 2009; 11 4 423 434
26. Feit F., Voeltz M. D., Attubato M. J., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol: 2007; 100 9 1364 1369
27. Karjalainen P. P., Porela P., Ylitalo A., et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J: 2007; 28 6 726 732
28. Ruiz-Nodar J. M., Marín F., Hurtado J. A., et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol: 2008; 51 8 818 825
29. Sorensen R., Hansen M. L., Abildstrom S. Z., et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet: 2009; 374 9706 1967 1974
30. Dewilde W. JM, Oirbans T., Verheugt F. WA., et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet: 2013; 381 9872 1107 1115
31. Hansen M. L., Sorensen R., Clausen M. T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med: 2010; 170 16 1433 1441
32. Lamberts M., Olesen J. B., Ruwald M. H., et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation: 2012; 126 10 1185 1193
33. Goto K., Nakai K., Shizuta S., et al. CREDO-Kyoto Registry Cohort-2 Investigators. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol: 2014; 114 1 70 78
34. Lamberts M., Gislason G. H., Lip G. YH., et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation: 2014; 129 15 1577 1585
35. Lamberts M., Gislason G. H., Olesen J. B., et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol: 2013; 62 11 981 989
36. Rha S-W. Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents. World J Cardiol: 2014; 6 4 148 153
37. Elmariah S., Mauri L., Doros G., et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet: 2015; 385 9970 792 798
38. Fiedler K. A., Maeng M., Mehilli J., et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol: 2015; 65 16 1619 1629
39. Miller C. S., Grandi S. M., Shimony A., Filion K. B., Eisenberg M. J. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol: 2012; 110 3 453 460
40. Lippi G., Favaloro E. J., Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost: 2014; 40 7 756 765
41. Alexander J. H., Becker R. C., Bhatt D. L., et al. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation: 2009; 119 22 2877 2885
42. Mega J. L., Braunwald E., Wiviott S. D., et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med: 2012; 366 1 9 19
43. Oldgren J., Budaj A., Granger C. B., et al. RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J: 2011; 32 22 2781 2789
44. Oldgren J., Wallentin L., Alexander J. H., et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J: 2013; 34 22 1670 1680
45. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
46. Dans A. L., Connolly S. J., Wallentin L., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation: 2013; 127 5 634 640
47. Alexander J. H., Lopes R. D., James S., et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med: 2011; 365 8 699 708
48. Gibson C. M., Mehran R., Bode C., et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J: 2015; 169 4 472 8.e5
49. Sarafoff N., Martischnig A., Wealer J., et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol: 2013; 61 20 2060 2066
50. Savonitto S., Ferri M., Corrada E. Fatal bleedings with prasugrel as part of triple antithrombotic therapy. Rev Esp Cardiol (Engl Ed): 2014; 67 3 225 226
51. January C. T., Wann L. S., Alpert J. S., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol: 2014; 64 21 e1 e76
52. Huber K., Airaksinen K. J., Cuisset T., Marín F., Rubboli A., Lip G. YH. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost: 2011; 106 4 569 571